Capítulo 10. 3. Intoxicaciones por psicofármacos


1) Nogue Xarau I. Intoxicación por benzodiacepinas, antidepresivos, fenotiazinas y barbituricos. Medicina Integral. 1992; 20:495-500.

2) Litovitz Tl, Smitz Af, Holm Kc. Anual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1989; 7: 495-502.

3) Aaron Cynthia K. Cyclic Antidepressant Poisoning. In: Rippe James M, Irvin Richard S, Fink Mitchell, Cerra Frank B. Intensive Care Medicine. Boston: Little,Brown, 1996; 1569-1578.

4) Hollister LE. Tricyclic antidepressant (part 1). N Engl J Med 1978; 299:1106-1110.

5) Hayes PE, Kristoff CA. Adverse reactions to five new antidepressants. Clin Pharm 1986; 5:471-478.

6) Hollister LE.Tricyclic antidepressants (part II). N Engl J Med 1978; 299:1168-1173.

7) Cassidy S, Henry J. Fatal toxicily of antidepressant drugs in overdore. Br Med J 1987; 295:1021-1026.

8) Shannon M, Merola J, Lovejoy FH Jr. Hypotension in severe tricyclic antidepressant overdose. Am J Emerg Med 1988; 6:439-443.

9)Jackson WK, Roose SP, Glassman AH. Cardiovascular toxicity of antidepressant medications. Psychopathology 1987; 20 (sppl 1):64-690.

10) Rudorfer MV. Cardiovascular changes and plasma drug levels after amitriptyline overdose. J Toxicol Clin Toxicol 1982; 19:67-71.

11) Rickels K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1992; 51 (suppl B): p9.

12) Pentel P, Benowitz N. Efficacy and mechanism of action of sodium bicarbonate in the trealment of desipramine toxicity in rats. J Pharmacol Exp Ther 1984;230:12-15.

13) Nelson JC, Jatlow PI. Nonlinear desipramine kinetics: Prevalence and importance. Clin Pharmacol Ther 1987; 41:666-671.

14) Javaid JI, Hendricks K, Davis JM. Alpha-1-acidglycoprotein involvement in high affinity binding of tricyclic antidepressants to human plasma. Biochem Pharmacol 1983; 32:1149-1153.

15) Pentel PR, Keyler DE, Haddad LM. Tricyclic, and newer antidepressants. En: Haddad Lester M. Winchester James F. Clinical Management of Poisoning and Drug Overdose. Philadelphia. W.B.Saunders: 1990; 636-655.

16) Connolly SJ, Mitchell LB, Swerdlow CD, Mason JW, Winkle RA. Clinical efficacy and electrophysiology of imipramine for ventricular tachycardial. Am J Cardiol 1984; 53:516-521.

17) Krikler DM, Curry PVL. Torsade de pointes, an atypical ventricular tachycardia. Br Heart J 1976; 38:117-121.

18) Richelson E. Antimuscarinic and other receptorblocking properties of antidepressants. Mayo Clin Proc 1983; 58:40-43.

19) Rosenberg J, Pentel PR, Pond S, Benowitz N. Hyperthermia associated with drug intoxication. Vet Hum Toxicol 1984; 26:413-417.

20) Malatynska E, Knapp RJ, Ikeda M, Yamamura HI. Antidepressants and seizure-interactions at the GABA-receptor chloride-ionophore complex. Life Sci 1988; 43:303-309.

21) Teba L, Schiebel F, Dedhia HV, Lazzell VA. Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressants overdose. Am J Emerg Med 1988; 6:566-569.

22) Hulten BA, Heath A. Clinical aspects of tricyclic antidepressant poisoning. Acta Med Scand 1982; 213:275-279.

23) Niemann JT, Bessen HA, Rothstein RJ, Laks MM. Electrocardiographic criteria for tricyclic antidepressant cardiotoxicity. Am J Cardiol 1986; 57:1154-1158.

24) Pentel P, Sioris L. Incidence of late arrhytmias following tricyclic antidepressant overdose. Clin Toxicol 1981; 18:543-547.

25) Foulke GE, Albertson TE, Walby WF: Tricyclic antidepressant overdose. Emergency department findings as predictors of clinical course. Am J Emerg Med 1986; 4:496-501.

26) Ellison DW, Pentel PR. Clinical features and consequences of seizures due to cyclic antidepressant overdose. Am J Emerg Med 1989; 7:5-12.

27) Shannon M, Merola J, Lovejoy FH. Hypotension in severe tricyclic antidepressant overdose. Am J Emerg Med 1988; 6:439-443.

28) Shannon M, Lovejoy FH. Pulmonary consequences of severe tricyclic antidepressant ingestion. Clin Toxicol 1987; 25:443-448.

29) Frommer DA, Kulig KW, Marx JA, Rumack B. Tricyclic antidepressant overdose. A review. JAMA 1987; 257:521-529.

30) Hulten B-A, Adams R, Askenasi R, et al. Activated charcoal in trcyclic antidepressant poisoning. Hum Toxicol 1988; 7:307-311.

31) Asbach HW, Holz F, Mohring K, Schuler HW: lipid hemodialysis versus charcoal hemoperfusion in imipramine poisonig. Clin Toxicol 1977; 11:211-215.

32) Hoffman JR, Votey SR, Bayer M, Silver L: Effect of hypertonic sodium bicarbonate in the treatment of moderate-to-severe cyclic antidepressant overdose. Am J emerg Med 1993; 11:336-341.

33) Buchman AL, Dauer J, Geiderman G: The use of vasoactive agents in the treatment of refractory hypotension seen in tricyclic antidepressant overdose. J clin Psychopharmacol 1990; 10:409-415.

34) Bessen HA, Niemann JT, Haskell RJ, Rothstein RJ: Effect of respiratory alkalosis in tricyclic antidepressant overdose. West J Med 1983; 139:373-379.

35) Bessen HA, Niemann JT: Improvement of cardiac conduction after hyperventilation in tricyclic antidepressant overdose. Clin Toxicol 1986; 23:537-542.

36) Martin TG, O´Connell JJ, Pentel PR, et al: Resucitation from severe cyclic antidepresant toxicity using cardiopulmonary bypass(abstract). Vet Hum Toxicol 1988; 30:354.

37) Southall DP, Kilpatrick SM: Imipramine poisoning: Survival of a child after prolonged cardiac massage. Br Med J 1974; 4:508-5513.

38) Brunn GJ, Keyler DE, Pond SM, Pentel PR: Reversal of desipramine toxicity in rats using drug-specific antibody Fab fragment: Effects on hypotension and interaction with sodium bicarbonate. J Pharmacol Exp Ther 1992; 260:1392-1403.

39) Greenblatt DJ, Shader RI. Drug therapy Benzodiazepines. N Engl J M 1974; 291: 1011-1015

40) Greenblatt DJ, Shader RJ, Abernathy DR, et al. Current status of benzodiazepines. N Engl J M 1983; 309: 410-416.

41) Cabrera bonet R, Cabrera Forneiro J. Aspectos epidemiológicos y médicos legales de las intoxicaciones por benzodiacepinas durante el año 1987 en el Servicio de Información Toxicologica del Instituto de Toxicologia. Rev Toxicol 1988; 5: 65-81.

42) Greenblatt DJ, Divol M, Abernathy DR et al. Current status of benzodiazepines ( Part I ). N Engl J Med 1983; 309: 354-358.

43) Study RE, Barker JL. Cellular mechanisms of benzodiazepines action. JAMA 1982; 187: 487-492.

44) Dennis T, Dubois A, Benavides J, Scatton B. Distribution of central omega1 y omega2 receptor subtypes in the monkey and human brain: An autoradiographic study with flunitrazepan and the omega1 selective ligand Zolpiden. F Pharmacol Exp Ther 1988; 274: 309-314.

45) Lader M. Clinical pharmacology of benzodiazepines. Annu Rev Med 1987; 38: 19-28.

46) Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. N Engl J Med 1982; 306:01081-1088.

47) Schentag JJ, Cerra FB, Calleri G et al. Pharmacokinetia and clinical studies in patiens with cimetidine associated mental confusion. Lancel 1979; 1: 177-181.

48) Nolla Salas J, Roca Tutusaus A. Motivo de ingreso y aspectos clínicos de la intoxicación aguda grave. Med Intensiva 1988; 12: 525-532.

49) Meyer BR. Benzodiazepines in the elderly. Med Clin North Am 1982; 66: 1017-1035.

50) Morris HH, Estes ML. Traveler´s amnesia: Transient global amnesia secundary to Triazolam. JAMA 1987; 258: 945-946.

51) Rall Theodore W. Hipnóticos y sedantes; etanol. En Goodman Gilman A, Rall Theodore W, Nies Alans y Taylor Palmer. Las bases farmacólogicas de la terapeutica. 8th ed. Méjico: Editorial Medica Panamericana, 1991; 345-380.

52) Finkle BS, McCloskey KL, Goodman LS. Diazepam and drug- associated deaths: A survey in the United States and Canada. JAMA 1979; 247: 429-434.

53) Robert James R, Tafusi John A. Benzodiacepinas. En Hadda Lester M, Winchester James F. Clinical Management of Poisoning and Drug Overdose. Philadelphia: W.B. Saunders, 1990; 800-819.

54) Busto V, Kaplan HL, Seller EM. Benzodiazepine associated emergencies in Toronto. Am J Psychiatry 1980; 137: 224-227.

55) Greenblatt DJ, Allen MD, Noel BJ et al. Acute overdosage with benzodiazepine derivatives. Clin Pharmacol Ther 1977; 21: 497-514.

56) Jatlow P, Dobular K, Bailey D. Serum diazepam concentrations in overdose: their significance. Am J Clin Pathol 1979; 72: 571-579.

57) Darragh A, Lambe R, Scully M et al. Investigation in man of the efficacy of a benzodiazepine antagonist Ro 15-1788. Lancet 1981; 2: 8-10.

58) Spivey WH. Flumazenil and seizures: Analisis of 43 cases. Clin Ther 1992; 14: 978-986.

59) Karavokiros KA, Tsipis GB. Flumazenil: A benzodiazepine antagonist. Ann Pharmacother. 1990; 24: 976-979.

60) Intoxicaciones por farmacos. En: Ewald Gregory A, Mckenzie Clark R. Manual de Terapéutica Médica. Barcelona. Masson-Little, Brown: 1996; 266-267.

61) Cabrera Bonet R, cabrera Forneiro J. Epidemiologia de las intoxicaciones por psicofarmacos en España. Phronesis 1990; 11: 97-103.

62) Winchester James F. Barbiturates, methacualone and primidone. En: Hadda Lester M, Winchester James F. Clinical Management of poisoning and Drug Overdose. Philadelphia: W.B.Saunders, 1990; 718-730.

63) Aaron Cynthia K, Burke Mary C, Restuccia Marc et al. Sedative-Hypnotic Poisoning. En Rippe James M, Irwin Richar S, Fink Mitchell, Cerra Frank B. Intensive Care Medicine. Boston. Little Brown, 1996; 1692-1701.

64) Nollas Salas J. Hipnosedantes. En Marruecos L, Nogue Santiago y Nolla Joan. Toxicologia clínica. Barcelona: Springer-Verlag Iberica, 1993; 59-72.

65) Sumner Dj, Kalk J, Whiting B. Metabolism of barbiturate after overdosage. Br Med J 1975; 1: 335-342.

66) Berveridge GW, Lawson AAH. Ocurrence of bullous lesions in acute barbiturate poisoning. Br Med J 1965; 1: 835-838.

67 Holzer P, Beubrer B, Dirnhofer R. Barbiturate poisonong and gastrointestinal propulsion. Arch Toxicol 1987; 60: 394_398.

68) Goldberg MJ, Berlinger WG. Treatment of phenobarbital overdose with activated charcoal. JAMA 1982; 247: 2400-2405.

69) Zawada ET, Nappi J, Done G et al. Advances in the hemodialysis management of phenobarbital overdose. South Med J 1983; 7: 6-14.

70) Henry J.A. Specific problems of drug intoxication. Br J Anaesth 1986; 58: 223-233.

71) Rickels K. Nonbenzodiazepine anxyolitics. Clinical usefulness. J Clin Psychiatry. 1983; 32: 48-55.

72) Sidney H Schnoll. Drogadicción, sobredosis y síndrome de abstinencia. En: Ayres stephen M, Ake Grenvik, Holbrook Peter R, Shoemaker Willian C. Tratado de Medicina Crítica y Terapia Intensiva. Buenos Aires: Editorial Médica Panamericana, 1996; 1203-1204.

73) Shannon MW, Eisen T, Linakis J. Clinical features of acute versus chronic lithium intoxication. Vet Hum Toxicol 1989; 31: 370-379.

74) Brady HR, Horgan JH. Lithium and the heart, unanswered questions. Chest 1988; 98:166-171.

75) Carol Ross S. Linden Christopher H. Neuroleptic Agents. En: Rippe James M, Irwin Richars S, Fink Mitchell, Cerra Frank B. Intensive Care Medicine. Boston. Little Brown. 1996; 1640-1647.

76) McGuigan M A. Phenothiazines. Clin Toxicol Rev 1981; 3:4-14.

77) Bass Robert R, Vargas Jonathan. En : Haddad Jester m, Winchester James F. The antipsychotic drugs. Philadelphia: W.B. Saunders: 1990; 780-793. 

78) Richelson E. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 1984; 45: 331-337.

79) Fowler NO, McCall D, Chou T. Electrocardiographic changes and cardiac arrhythmias in receiving psychotic drugs. Am J Cardio 1981; 37: 223-228.

80) Feldman V. Serious reactions to phenothiazines. J Pediatr 1976; 89: 163-170.

81) Cook FE. Davis RG. Russo LS. Internuclear ophthalmoplegia caused by phenothiazine intoxication. Arch Neurol 1981; 38: 465-468.

82) MacKnow CH. Verhulst HL. Crotty JJ. Overdose effects and danger from tranquilizing drugs. JAMA 1963; 185: 452-456.

83) Baker PB. Merigian KS, Roberts JR. Hyperthermia, hypotension, hypertonia and coma in a masive thioridazine overdose. Am J Emerg Med 1988; 6: 346-349.

84) Tam CW. Olin BR. Ruiz AE. Loxapine associated rhabdomyolysis and acute renal failure. Arch Intern Med 1980; 140: 975-982.

85) Barbeau A. Parkinson´s disease: Clinical features and etiopathology. En: Vinton PJ, Bruyn GW, Klawans HL: Extrapyramidal Disorders: Handbook of Clinical Neurology. Amsterdam, Elsevier; 1986; vol 49: 87-152.

86) Donna Seger. Phenytoin and other anticonvulsants. En: Hadda Lester M, Winchester James F. Philadelphia. W.B. Saunders: 1990; 877-893.

87) Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures: Recomendations for usage. JAMA 1983; 249: 762-765.

88) Kearney Thomas E, Aaron Cynthia K. Anticonvulsant Toxicity. En: Rippe James M, Irwin Richars S, Fink Mitchell, Cerra Frank B. Intensice Care Medicine. Boston. Littel Brown. 1996; 1640-1647.

89) Borofsky LG, Louis B, Kutt H. Diphenylhydantoin efficacy, toxicity and dose-serum relationships in children. J Pediatric 1972; 81: 995-998. 

90) Tenckhoff H, Sherrard DJ, Hickman O. Acute diphenylhydantoin intoxication. Am J Dis Chil 1968; 116: 422-445.

91) Masur H, Elger CE, Ludolph AC, Galanski M. Cerebellar atrophy following acute intoxication with phenytoin. Neurology 1989; 39. 432-433.

92) Luschser TF, Siegenthaler Zuber G, Kuhlmann V. Severe hipernatremia coma due to diphenylhydantoin intoxication. Clin Nephr 1983; 20: 268-271.

94) Baehler RW, Work J, Smith W. Charcoal hemoperfusion in the therapy of methsuximide and phenytoin overdose. Arch Intern Med 1980; 40: 1466-1469.

95) Covanis A, Gupta AK, Jeavons PM. Sodium valproate: Monotherapy and politherapy. Epilepsia 1982; 23: 693-697.

96) Schwabel R, Rambeck B, Janson F. Fatal intoxications with sodiun valproate 1984; 1: 221-224.

97) Garnier R, Boudignat O, Fournics PE. Valproate poisoning. Lancet 1982; 1: 97-101.

98) Eeg-Olofsson O, Lindskog V. Acute intoxication with valproate. Lancet; 2: 1039-1309.

99) Mortensen PB, Hansen HE, Pedersen B. et al. Acute valproate intoxication: Biochemical investigations and hemodialysis treatment. Int J Clin Pharmacol ther Toxicol 1983; 21: 64-67.

100) García Guasch R, Nogués Tomás S. Anticonvulsivantes. En:Marruecos Luis, Nogue Santiago y Nolla Joan. Toxicologia clinica. Barcelona: Springer-Verlag Iberica, 1993: 127-141.

101)Macdonald R. Antiepilephia Drugs Actions. Epilepsia 1988; 30: S19-S28.

102) Rall Theodore W, Schleifer Leonard S. Fármacos efectivos en el tratamiento de la epilepsia. En: Goodman Gilman A, rall Theodore W, Nies Alans, taylor Palmer. Las bases fármacologicas de la terapéutica. Mejico: Editorial Medica Panamericana 1991; 433-457.

103) Rockoff S, Baselt RC. Severe carbamazepine poisoning. Clin Toxicol 1981; 18: 935-938.

104) Boldy DAR, Heath A, Ruddock S, Vale JA, Prescott LF. Activated charcoat for carbamazepine poisoning. Lancet 1987; 2: 1027.

105) Zuber M, Elsasser S, Ritz R. Flumazenil in severe intoxication with carbamazepine. Eur Neurol 1988; 28: 161.

106) Nilsson C, Sterner G, Idvall J. Charcoal hemoperfusion for treatment of serious carbamazepine poisoning. Acta Med Scand 1984; 216: 137-141.

107) Ramsay RE. Advances in the pharmacotherapy of epilepsy. Epilepsia 1993; 34: 9-14.